KARACHI: Pakistani health authorities have granted emergency use authorization to Russian COVID-19 vaccine, Gam-COVID-Vac or Sputnik V to be used in Pakistan, hoping that the first shipment of the vaccine would reach Pakistan by the end of current month, The News has learnt. In all likelihood, double dose of Sputnik V in Pakistan would cost double the rates at which it is available in India.
“The registration board of the Drug Regulatory Authority of Pakistan (DRAP) in its 299th meeting on Friday, granted emergency use authorization to Russian made COVID-19 vaccine Gam-COVID-Vac, whose trade name is Sputnik V. A local pharmaceutical firm, AGP Limited had applied for registration, marketing and distribution of the vaccine in Pakistan,” an official of the DRAP told The News on Saturday.
Pakistani authorities have already granted emergency use authorization to one of the vaccines developed by China’s state-owned Sinopharm as well as to British-Swedish vaccine manufacturer Oxford-AstraZeneca’s AZD1222/ Covisheild vaccine but so far none of the vaccines have been supplied to the country where around 11,000 people have lost their lives due to the pandemic.
DRAP officials said a committee of experts comprising top infectious diseases experts and pathologists for the evaluation of clinical trials data for registration of COVID-19 vaccines on January 21, 2020 recommended the granting of Emergency Use Authorization for Sputnik-V vaccine in Pakistan.
“The decision to grant Emergency Use Authorization was announced by the registration board of the Drug Regulatory Authority of Pakistan during its meeting being held at 4:00pm yesterday (Friday) following which, the first shipment of the vaccine is expected to reach Pakistan by next week”, the official added.
The vaccine, developed by M/s Gamaleya National Center of Epidemiology and Microbiology, with support from the Russian Direct Investment Fund, a sovereign fund of the Russian Federation, has been approved in 11 countries, including Russia, Argentina, Hungary and UAE and registration in the European Union has also been filed.
The Phase III study comprising data of 19,866 subjects of which 10.8pc were elderly aged 60 years and above determined that the vaccine has a good safety profile with efficacy of over 91pc, with complete protection against severe cases of COVID-19.
“All parameters of the vaccine including its efficacy, immunogenicity and safety were found to be acceptable even across the elderly age group”, the DRAP official added. To a query, the official said the importer has assured the authorities to make the first shipment of vaccine available in Pakistan within next 7-10 days, adding that the first shipment of the vaccine would hopefully comprise 50,000 doses.
The Sputnik V vaccine’s liquid form must be stored at minus 18 degrees Celsius or below to maintain its stated 92pc efficacy, one of the members of the expert committee that recommended for its emergency use authorization in Pakistan, said adding that Pakistan would require a new cold chain mechanism to maintain the efficacy of the vaccine in the country.
Officials at the National Health Services, Regulations and Coordination told The News that price of the vaccine would be fixed by the pricing board of DRAP in the coming days. Interestingly, Russian Development Investment Fund (RDIF), which is backing the Sputnik V vaccine, is ready to supply the vaccine at less than $10 per dose, Russian and Indian media reported on Thursday.
But Pakistani health authorities said keeping in view the unavailability of the COVID-19 vaccine in the country at the moment, when neighbouring countries like India, Bangladesh and others had already started vaccinating their people, acquiring the vaccine from all sources was their first priority.
“Our first priority is to get the maximum number of vaccine doses as early as possible. We are going to get our share of vaccines from the Covax facility in next few weeks but at the moment, we are trying desperately to get hold of any vaccine to inoculate our frontline workers, the top priority”, the official added.
On lesser prices of the vaccines in India, he said actually Indians were manufacturing European, Russian and even Chinese vaccines at their own production facilities including Serum Institute of India, Bharat Biotech and others. “We are going to bring in finished form to start with. So it will cost much more than if we could have manufactured locally,” he added.
17 million boys and girls aged between 5 and 9 are out of schools and 4.9 million children between age of 10 and 12...
Charge adjustment reflects reduced capacity availability from 747MW to 483MW due to unavailability of ST-16 turbine
Muhammed Ashraf Jalali and Saad Hussain Rizvi, were tried in absentia as Pakistan did not force men to appear at...
Responding to various points, raised by lawmakers on private members day and winding up debate on FBR digitalization
Floods claimed over 1,700 lives, with one-third of the victims being children
Salamat said that there are 2,100 small and big units of power looms in Ghulam Mohammadabad, main area of power looms...